The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy
Open accessAbstract
Immunotherapy includes immune checkpoint inhibitors (ICI) such as antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death protein/programmed death ligand 1 (PD-1/PD-L1) axis. Experimental and clinical evidence show that immunotherapy based on immune checkpoint inhibitors (ICI) provides long-term survival benefits to cancer patients in whom other conventional therapies have failed. However, only a minority of patients show high clinical benefits via the use of ICI alone. One of the major factors limiting the clinical benefits to ICI can be attributed to the lack of immune cell infiltration within the tumor microenvironment. Such tumors are classified as "cold/warm" or an immune "desert"; those displaying significant infiltration are considered "hot" or inflamed. This review will provide a brief summary of different tumor properties contributing to the establishment of cold tumors and describe major strategies that could reprogram non-inflamed cold tumors into inflamed hot tumors. More particularly, we will describe how targeting hypoxia can induce metabolic reprogramming that results in improving and extending the benefit of ICI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As noted above, based on their TME, tumors can be categorized into two general types: ‘hot’ tumors, distinguished by an immunosupportive TME and a positive response to immunotherapy, and ‘cold’ or non-immune reactive tumors exhibiting a poor response to immunotherapy and characterized by an immunosuppressive TME (Zhang et al., 2022; Benoit et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Benoit et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“‘Hot’ tumors show enrichment in CD8+ lymphocytes and M1 TAMs, with low infiltration of MDSCs or CAFs, resulting in a more favorable response to immunotherapy.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Benoit et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, the TME of ‘cold’ tumors is defined by the presence of more Tregs than CD8+ lymphocytes and high infiltration of M2 TAMs, MDSCs, and CAFs (Benoit et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Benoit et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451 · cited 4×
“HIF-1 is composed of two subunits, HIF-1α and HIF-1β; both have basic helix–loop–helix domains and can form a heterodimer and bind to the promoter of target genes.”
BackgroundInfluentialRetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952 · cited 1×
“This activation is characterized by the expression of pattern recognition receptors (PRRs) and binding of pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) [18].”
BackgroundCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 2×
“The TGF-β blockade in combination with anti-PD-L1 treatment contributes to an increase in T cell infiltration and improvement in tumor regression in mouse models [41].”
BackgroundHypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645 · cited 2×
“HIF2α can also bind to HIF-1β, and it plays a role in vascularization, pulmonary development, and erythropoiesis [118].”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The CAR-T cell approach showed significant efficacy in acute lymphoid leukemia and lymphoma [114,115].”
BackgroundComprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409 · cited 1×
“Altered or warm tumors have low infiltration of immune cells, either in the tumor margin only (altered-excluded tumors) or in both areas (altered-immunosuppressed tumors) [7,8].”
BackgroundTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · cited 1×
“TMB has been proposed as a biomarker of the response to anti-PD-1 therapy [12].”
Background
Cited by
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
“The constrained clinical advantages observed in a relatively minor proportion of patients can be attributed to various factors, chief among them being the dearth or restricted infiltration of immune cells within the microenvironment [183].”
BackgroundNanomaterials in the Wound Healing Process: New Insights and Advancements
Sangnim, T., Puri, V., Dheer, D., Venkatesh, D. N., Huanbutta, K., & Sharma, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030300 · Cited by 98
The future of affordable cancer immunotherapy
Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 86
Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer
Din, S. M. U., Streit, S., Huynh, B. T., Hana, C. K., Abraham, A. N. J., & Hussein, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042060 · Cited by 69
“Moreover, HIF-1 α also has the capability of binding to the promoter of the PD-L1 gene, leading to the upregulation of this gene, further deactivating T cells and promoting the escape of the immune system in a manner that may lead to resistance against immune checkpoint inhibitors [32,34].”
BackgroundAbreu, M. M., Chocron, A. F., & Smadja, D. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1487296 · Cited by 59
NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10
Sun, H., Fu, M., Li, J., Xuan, Z., Bai, Y., Zhang, Z., Liu, Y., Zhang, Z., Xue, Y., Zheng, J., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01805-5 · Cited by 27
“For "cold tumors" such as PCa, T cell infiltration within the tumor is small, and immune check-point inhibitors have limited effects [50].”
BackgroundOncolytic Virus‐Like Nanoparticles for Tumor‐Specific Gene Delivery
Li, Y., Yang, H., Zong, X., Li, X., Yuan, P., Yang, C., Chen, X., Yan, X., Wen, Y., Zhu, T., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202314898 · Cited by 17
Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
Nemunaitis, J. J., Stanbery, L., Willoughby, D., Bognar, E., Brun, S., Walter, A., Monk, B. J., Rocconi, R. P., Choucair, K., & Coleman, R. L. (2023) · Cancers · doi:10.3390/cancers15235616 · Cited by 15
“Transfer of cold to hot tumor microenvironment has been well described as an optimal state of CPI activity [168–170].”
BackgroundMicrophysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
From cold to hot tumors: feasibility of applying therapeutic insights to TNBC
Yan, S., Sun, X., & Wang, K. (2025) · Discover Oncology · doi:10.1007/s12672-025-03745-z · Cited by 17
“In addition to the fundamental molecular differences, cold and hot tumors demonstrate distinct clinical behaviors that have significant implications for prognosis and treat-ment outcomes [14].”
Nanoimmunotherapy: the smart trooper for cancer therapy
Parveen, S., Konde, D. V., Paikray, S. K., Tripathy, N. S., Sahoo, L., Samal, H. B., & Dilnawaz, F. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002308 · Cited by 15
New strategies for the management of triple-negative breast cancer
Riaz, F. (2023) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000927 · Cited by 10
Epigenetic regulation of cGAS and STING expression in cancer
Zhao, C., Guo, S., & Ge, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112556 · Cited by 8
Baldi, S., Alnaggar, M., AL-Mogahed, M., Khalil, K., & Zhan, X. (2025) · The EPMA Journal · doi:10.1007/s13167-025-00403-w · Cited by 8
“By contrast, “cold” tumors that have few or no TILs respond poorly to this type of therapy [60, 71, 72].”
Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy—A Translational Model
Swamy, K. (2023) · Vaccines · doi:10.3390/vaccines12010007 · Cited by 7
Immunocompetent tumor-on-a-chip: A translational tool for drug screening and cancer therapy
Liang, A., Tao, T., Chen, J., Yang, Y., Zhou, X., Zhu, X. M., & Yu, G. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104716 · Cited by 6
Signature Gene Mutations in Colorectal Cancer: Potential Neoantigens for Cancer Vaccines
Yoon, J., Moon, H., Jeon, Y., Choe, S., & Yoon, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104559 · Cited by 7
“In cold tumors, immunotherapy is less effective, necessitating the development of effective strategies to overcome the immunosuppressive [18].”
Gutiérrez-Sandoval, R., Gutiérrez-Castro, F., Muñoz-Godoy, N., Rivadeneira, I., Sobarzo, A., Alarcón, L., Dorado, W., Lagos, A., Montenegro, D., Muñoz, Í., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061299 · Cited by 6
“While CAR-T cells [13] have shown remarkable efficacy in hematologic malignancies, their application in solid tumors has been less successful due to poor tumor penetration [14], antigenic heterogeneity, and systemic toxicities such as cytokine [15] release syndrome (CRS).”
Handoko, H., Adham, M., Rachmadi, L., Wibowo, H., & Gondhowiardjo, S. A. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s452117 · Cited by 4
“44,45 We need to devise a new strategy for dealing with such a tumour subset to improve therapeutic outcomes in the future.”
BackgroundMonnikhof, M., Schakelaar, M. Y., Meulenbroeks, C., Quist, M., Perzolli, A., Selten, A., Koster, C., Maassen, D. S. C., Canelo, A. M., Fredriks, M., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf099 · Cited by 9
“59 For MB patients lacking infiltrating cytotoxic lymphocytes, ICI treatment can be combined with cellular infusions (e.g. CAR-T cells or NK cells) of which the efficiency remains to be studied in vivo.”
Experimental models for developing oncolytic virotherapy for metastatic prostate cancer
Chen, Y.-C., & Figueiredo, M. L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1626432 · Cited by 3
Dighe, S., & Jain, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104521 · Cited by 3
Jafari, Z., Raoufi, A., Athari, S. S., Bahramkiya, S., & Jafari, D. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02610-4 · Cited by 2
“The selective loss of highly immunogenic clones further weakens antigenicity, limiting immune recognition and promoting therapeutic resistance [162].”
Zhang, H., Hong, K., Song, Q., Zhu, B., Wu, G., & Yu, B. (2024) · Journal of Cancer · doi:10.7150/jca.100430 · Cited by 3
“In our study, we characterized the immune landscape in different groups, and found that the patients with high-risk scores were in relevance with low immune infiltration, low expression of immune checkpoints, and high tumor purity, corresponding to an immune-desert phenotype [59].”
BackgroundKansal, H., Chopra, V., Garg, K., & Sharma, S. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04137-z · Cited by 1
Advances in Cancer Immunotherapy for Solid Tumors
Gabizon–Peretz, S., & Kluger, H. M. (2026) · Advanced Science · doi:10.1002/advs.76020 · Cited by 2
Dong, J., Fu, C., Li, M., Wang, Z., & Li, B. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102326 · Cited by 1
Dong, J., Qi, Y., Sha, S., Fu, C., Xu, X., & Li, B. (2025) · BMC Cancer · doi:10.1186/s12885-025-14119-7 · Cited by 1
“Shows potential as an immune amplifier capable of reprogramming the tumor microenvironment, triggering an inflammatory response and sensitizing "cold" tumors to immune checkpoint blockade therapies [5, 17, 18, 22].”
NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10Preprint
Sun, H., Fu, M., Li, J., Xuan, Z., Bai, Y., Zheng, Z., Liu, Y., Zhang, Z., Xue, Y., Zheng, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3871999/v1
Frequent CT Scan Radiation Activates Interferon Responses and Antitumor T-Cell ImmunityPreprint
Dong, J., Wang, Z., Li, M., Li, B., & Fu, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4228041/v1
Lin, P., Wen, Y., Zhao, J., Zhang, F., Su, Y., Yu, H., Hx, Y., Li, Q., Liu, C., Hu, Z., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015428
“7 11–13 Most patients derive limited clinical benefit due to insufficient tumor-infiltrating lymphocytes (TILs).”
Lu, X., Cui, X., Chen, H., Zhang, J., Zhao, S., Yang, B., Yang, Y., Du, N., Ma, W., An, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1795481
Naing, A., Lin, C. Y., Patel, M. R., Curigliano, G., Burris, H. A., Thistlethwaite, F. C., de Braud, F., Minchom, A., Ascierto, P. A., Wake, M., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013540
An Intrinsically Therapeutic Mn/Se Supramolecular Hydrogel for Cancer Immunotherapy
Peng, L., Kong, Y., Yan, J., Xia, G., Xing, W., Shen, M., Wang, C., & Zheng, Z. (2026) · Advanced Functional Materials · doi:10.1002/adfm.77396
Yang, N., Zhou, Y., Zhang, Y., Yi, X., Mu, Y., Sun, F., Han, M., Liu, C., Yin, M., Xu, H., et al. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127286
Abrar, K., Hameed, H., Younas, K., Ghumman, S. A., Hameed, A., & Mushtaq, T. (2026) · International Journal of Polymeric Materials · doi:10.1080/00914037.2026.2717612
Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation
Xu, W., Shuhan, L. I. U., Sun, L., Bi, Y., Lin, Z., Wang, T., Ren, X., & An, R. (2026) · Oncogene · doi:10.1038/s41388-026-03961-z
“…interstitium but rich in TAMs, Tregs, and MDSCs, creating a highly immunosuppressive micro-environment; immune rejecting, where effector T cells are restricted to the fi brotic mesenchyme and unable to penetrate the tumor core due to a physical barrier formed by dense extracellular matrix [2, 3].”
Dang, X., Zhang, T., Li, H., & Liu, Y. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04483-6
Metadata
- Authors
- Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B.
- Affiliations
- Luxembourg Institute of Health (LU)
- Centre François Baclesse (LU)
- Centre Hospitalier de Luxembourg (LU)
- Corresponding author
- Janji, Bassam
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-07-05
- Volume
- 12
- Issue
- 13
- Pages
- 1787
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC10341162
- OpenAlex
- W4383375914
- Cited by
- 39
- References
- 149
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 11 · 2023: 5
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- FNRS Televie (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Roche Pharma 2023 (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- RCMS foundation (INCOM BIOM) (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Luxembourg National Research Fund (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Kriibskrank Kanner Foundation, Luxembourg (2019) (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Action LIONS Vaincre le Cancer Luxembourg (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Stiftelsen Cancera (CombiN 2023) (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- cold tumors, tumor microenvironment, cancer immunotherapy, immune checkpoint inhibitors, CTLA-4, PD-1/PD-L1 axis, tumor immune infiltration, tumor hypoxia, metabolic reprogramming, tumor reprogramming
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Immunotherapy, Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.